The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery diseaseThomas O. Bergmeijer, Paul A. Gurbel, Udaya S. Tantry et al.|Thrombosis and Haemostasis|2014Cited by 32
Coronary Computed Tomography Angiography in Prediction of First Coronary EventsGöran Bergström, Tomas Jernberg, David Erlinge et al.|JAMA|2025Cited by 27
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery diseaseStefan James, David Erlinge, Joseph A. Jakubowski et al.|Thrombosis and Haemostasis|2014Cited by 21
Multicohort assessment of plasma metabolomic measurements across the atherosclerosis continuumSergi Sayols-Baixeras, T Fall, Kamalita Pertiwi et al.|medRxiv|2026Cited by 0